Sertraline hydrochloride

CHF 68.00
In stock
CDX-S0088-M01010 mgCHF 68.00
CDX-S0088-M05050 mgCHF 272.00
More Information
Product Details
Synonyms (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride; CP 51,974-1; Lustral; Seserine; Zoloft
Product Type Chemical

C17H17NCl2 . HCl

MW 342.69
CAS 79559-97-0
RTECS QJ0352070
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml) or ethanol (10mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Smiles ClC(C=C1)=C(Cl)C=C1[C@H]2C3=C(C=CC=C3)[C@@H]([NH2+]C)CC2.[Cl-]
Shipping and Handling
Shipping AMBIENT
Short Term Storage -20°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Sertraline is a tetraline that inhibits monoamine transporters and acts as a potent highly selective serotonin reuptake inhibitor (SSRI), with affinity for the serotonin transporter (SERT), increasing availability of serotonin (5-hydroxytryptamine; 5-HT) in the brain and leading to antidepressant, anxiolytic and antiobsessional effects. Sertraline binds also to the dopamine transporter (DAT) and the σ1 receptor (but not the σ2 receptor) with 100-fold lower affinity. It acts as an antagonist of the σ1 receptor, and is able to reverse σ1 receptor-dependent actions of fluvoxamine, a potent agonist of the receptor, in vitro. Sertraline displays antiproliferative activity on human colorectal carcinoma cells.

Product References

(1) B.K. Koe, et al.; J. Pharmacol. Exp. Ther. 226, 686 (1983) | (2) W.M. Welch, et al.; J. Med. Chem. 27, 1508 (1984) | (3) J. Heym & B.K. Koe; J. Clin. Psychiatry 49, 40 (1988) | (4) M. Tatsumi, et al.; Eur. J. Pharmacol. 340, 249 (1997) | (5) G. MacQueen, et al.; CNS Drug Reviews 7, 1 (2001) | (6) H.R. Khouzam, et al.; Compr. Ther. 29, 47 (2003) | (7) J.H. Meyer, et al.; Am. J. Psych. 161, 826 (2004) | (8) B. Lowe, et al.; J. Affect. Disord. 87, 271 (2005) | (9) Y. Albayrak & K. Hashimoto; Adv. Exp. Med. Biol. 964, 153 (2017)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.